Developer docs
API playgroundTry for free, no card

Search company profiles

Mundipharma

Full company profile

uuid003w6ic

Namestring
Mundipharma
Legal namestring
Mundipharma International Limited
Websiteurl
mundipharma.com
Company typeenum
Private
Founded yearint
1992
Descriptiontext

Mundipharma is a privately held, Cambridge, UK-headquartered pharmaceutical group that operates as a federation of independently associated national companies across more than 40 countries, employing between 1,001 and 5,000 people globally. The group develops, manufactures, and commercialises prescription medicines across four core therapeutic areas: pain management (anchored by the OxyContin, OxyNorm, MST Continus, and Targin franchises), respiratory disease (Flutiform and related inhaled combination products), oncology, and infectious diseases (notably REZZAYO/rezafungin for candidemia and invasive candidiasis).

The company's revenue model is built on branded specialty pharmaceuticals sold through prescriber, hospital, and retail pharmacy channels, supplemented by geographic licensing and partnership arrangements — most recently a 2026 US commercialisation agreement with CorMedix for REZZAYO. Its underlying technology base is predominantly small-molecule formulation and inhalation-device engineering, extended through the 2018 acquisition of Cinfa Biotech into biosimilars. Late-stage R&D is concentrated on REZZAYO, with Phase III ReSPECT data reported in April 2026 and FDA/EMA submissions planned for 2H 2026 and Q3 2026 respectively, targeting a US market opportunity described as greater than $2 billion.

Operationally, Mundipharma has been actively reshaping its portfolio: it divested its Consumer Health business to iNova Pharmaceuticals in January 2024 to focus on prescription specialty franchises, and continues to operate within a governance framework that includes board-level ESG oversight and a published Modern Slavery Statement. The group's historical association with the Sackler family remains a defining reputational context given the OxyContin franchise.

Short descriptiontext

Mundipharma is a privately held pharmaceutical group operating through independent associated companies in 40+ countries, developing and commercialising branded prescription medicines in pain, respiratory, oncology, and infectious diseases, anchored by OxyContin, Targin, Flutiform, and the late-stage antifungal REZZAYO.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices33 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, pain management therapeutics, antifungal medications, respiratory treatments, oncology supportive care
Industry5 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAN
Controlled Substances & Compliance-Focused Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Prescription Pharmaceutical Products
TypeOne Time License
Description

Mundipharma generates revenue through the development, manufacture, and sale of prescription pharmaceutical products across therapeutic areas including pain management, respiratory, oncology, and infectious diseases. The company operates through a global network of independent associated companies.

mundipharma.com
2DefenCath
TypeSubscription Recurring
Description

CorMedix reported record 2025 net sales of approximately $260 million driven by DefenCath's TDAPA reimbursement. CorMedix is Mundipharma's US licensee for REZZAYO.

seekingalpha.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1REZZAYO
Description

Antifungal medication (rezafungin) for invasive fungal infections

mundipharma.com
+1 more record
Core offering1 text field

Mundipharma develops, manufactures, and commercializes prescription pharmaceutical products across four core therapeutic areas: pain management (opioid and non-opioid analgesics such as oxycodone and morphine formulations), respiratory conditions (asthma/COPD inhalers), oncology (treatments and supportive care), and infectious diseases (antifungal prophylaxis including REZZAYO). The company operates through a network of independent associated companies distributing products in 40+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 60.7% fungal-free survival at Day 90 for REZZAYO versus 59.0% for standard regimen in Phase III ReSPECT trial
+1 more record
Product overview1 text field

Mundipharma is a global pharmaceutical company with a diversified portfolio of prescription medicines and consumer health products. The company operates as a network of independent associated companies and focuses on specialty healthcare solutions. Their therapeutic areas include pain management (opioid analgesics such as OxyContin, OxyNorm, MST Continus, Zytram, Targin), respiratory treatments (Flutiform for inhalation), oncology (Zevalin, Pelmeg), and infectious diseases (REZZAYO antifungal). The portfolio comprises both proprietary developed products and licensed brands, with products available across multiple international markets through their global office network spanning over 40 countries.

Product and service11 records
1REZZAYO (rezafungin)
CategoryAntifungal therapeutics
Description

Antifungal medication for the prophylaxis and treatment of invasive fungal diseases, including for patients undergoing allogeneic hematopoietic stem cell transplantation. Co-developed with CorMedix.

2Flutiform (fluticasone propionate/formoterol fumarate)
CategoryRespiratory therapeutics
Description

Pressurized metered-dose inhaler for the management of asthma and COPD, available in 50/5µg, 125/5µg, and 250/10µg dosage strengths. Licensed from Jagotec AG.

3MST Continus (morphine sulfate)
CategoryPain management
Description

Prolonged-release morphine sulfate tablets for pain management, available in 5mg, 10mg, 15mg, 30mg, 60mg, 100mg, and 200mg dosages.

4OxyContin (oxycodone hydrochloride)
CategoryPain management
Description

Prolonged-release oxycodone tablets for chronic pain management, available in 5mg, 10mg, 20mg, 40mg, and 80mg dosages.

5OxyNorm (oxycodone hydrochloride)
CategoryPain management
Description

Injectable oxycodone solution and infusion for acute pain management, available as 10mg/ml solution in 1ml and 2ml ampoules.

6Zytram (tramadol hydrochloride)
CategoryPain management
Description

Prolonged-release tramadol tablets for pain management, available in 150mg, 200mg, 300mg, and 400mg dosages.

7Zytram BID (tramadol hydrochloride)
CategoryPain management
Description

Prolonged-release tramadol tablets for pain management, available in 75mg twice-daily dosage.

8TARGIN (oxycodone/naloxone)
CategoryPain management
Description

Combination prolonged-release oxycodone/naloxone tablets used in pain management.

9BUTRANS (buprenorphine transdermal)
CategoryPain management
Description

Registered transdermal pain management product of the Mundipharma network.

10ZEVALIN
CategoryOncology therapeutics
Description

Registered oncology product in the Mundipharma network used in cancer treatment.

11PELMEG (pegfilgrastim)
CategoryOncology therapeutics
Description

Registered oncology supportive-care biosimilar in the Mundipharma network.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-27
Description

Mundipharma and CorMedix partnered on the development and commercialization of REZZAYO (rezafungin) for prophylaxis of invasive fungal diseases. The Phase III ReSPECT trial met its primary endpoint demonstrating non-inferiority with 60.7% fungal-free survival at Day 90. The companies plan to submit for FDA approval in 2H26 and EMA approval in Q3 2026. The US market opportunity is estimated to exceed $2 billion.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty pharmaceutical company with branded specialty franchises including pain management. Operates across multiple therapeutic areas with a similar specialty-pharma profile to Mundipharma, including legacy opioid exposure.

TypeDirect peer
Description

Pharmaceutical company historically anchored by OxyContin and other opioid analgesics, sharing therapeutic focus and brand portfolio overlap with Mundipharma's pain franchise. Closely comparable on opioid product positioning.

TypeEmerging player
Description

Clinical-stage biotechnology company developing antifungal therapies including rezafungin-related programs. Directly comparable to REZZAYO's therapeutic area and competitive positioning in the antifungal space.

TypeRegional player
Description

Specialty pharmaceutical company with strong presence in Middle East, North Africa, and other regional markets, plus specialty injectable and branded portfolio. Comparable to Mundipharma on specialty pharma positioning with regional market overlap.

TypeDirect peer
Description

Privately-held German specialty pharmaceutical company with a strong pain management franchise (including branded opioid and non-opioid analgesics) and global commercial operations. Highly comparable to Mundipharma in therapeutic focus and privately-held, specialty-pain-led business model.

6Endo International
TypeDirect peer
Description

Specialty pharmaceutical company with significant pain management portfolio (including opioid analgesics) and branded specialty franchises. Comparable to Mundipharma across pain management focus and specialty pharma positioning, though Endo has faced opioid-related litigation.

TypeBroad incumbent
Description

European-headquartered specialty pharmaceutical company with consumer health and specialty care portfolio across multiple therapeutic areas. Comparable as a European specialty pharma peer with similar multi-country distribution model.

TypeBroad incumbent
Description

Global pharmaceutical company with broad specialty and generics portfolio across multiple therapeutic areas. Comparable to Mundipharma's diversified specialty/generic-style positioning across pain, respiratory, and other areas.

TypeBroad incumbent
Description

Global pharmaceutical company with established antifungal franchise and specialty care portfolio. Comparable as a broader incumbent in antifungal/anti-infective therapeutics where REZZAYO competes, and a meaningful peer in specialty pharma.

TypeBroad incumbent
Description

Global pharmaceutical major with established respiratory franchise (including inhaler products competing with Flutiform) and broad specialty portfolio. Comparable as a broad incumbent in respiratory therapeutics where Mundipharma operates.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mundipharma

Specialty Pharmaceuticalsmundipharma.com

Mundipharma is a privately held pharmaceutical group operating through independent associated companies in 40+ countries, developing and commercialising branded prescription medicines in pain, respiratory, oncology, and infectious diseases, anchored by OxyContin, Targin, Flutiform, and the late-stage antifungal REZZAYO.

What Mundipharma does

Mundipharma is a privately held, Cambridge, UK-headquartered pharmaceutical group that operates as a federation of independently associated national companies across more than 40 countries, employing between 1,001 and 5,000 people globally. The group develops, manufactures, and commercialises prescription medicines across four core therapeutic areas: pain management (anchored by the OxyContin, OxyNorm, MST Continus, and Targin franchises), respiratory disease (Flutiform and related inhaled combination products), oncology, and infectious diseases (notably REZZAYO/rezafungin for candidemia and invasive candidiasis).

The company's revenue model is built on branded specialty pharmaceuticals sold through prescriber, hospital, and retail pharmacy channels, supplemented by geographic licensing and partnership arrangements — most recently a 2026 US commercialisation agreement with CorMedix for REZZAYO. Its underlying technology base is predominantly small-molecule formulation and inhalation-device engineering, extended through the 2018 acquisition of Cinfa Biotech into biosimilars. Late-stage R&D is concentrated on REZZAYO, with Phase III ReSPECT data reported in April 2026 and FDA/EMA submissions planned for 2H 2026 and Q3 2026 respectively, targeting a US market opportunity described as greater than $2 billion.

Operationally, Mundipharma has been actively reshaping its portfolio: it divested its Consumer Health business to iNova Pharmaceuticals in January 2024 to focus on prescription specialty franchises, and continues to operate within a governance framework that includes board-level ESG oversight and a published Modern Slavery Statement. The group's historical association with the Sackler family remains a defining reputational context given the OxyContin franchise.

Mundipharma firmographics

Firmographics
Name
Mundipharma
Legal name
Mundipharma International Limited
Website
https://mundipharma.com
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Mundipharma is a privately held pharmaceutical group operating through independent associated companies in 40+ countries, developing and commercialising branded prescription medicines in pain, respiratory, oncology, and infectious diseases, anchored by OxyContin, Targin, Flutiform, and the late-stage antifungal REZZAYO.
Ownership category
akta.pro rank

Mundipharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAN
Controlled Substances & Compliance-Focused Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Prescription pharmaceuticals
  • Pain management therapeutics
  • Antifungal medications
  • Respiratory treatments
  • Oncology supportive care

Where Mundipharma is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices33 records

Markets served

Mundipharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Prescription Pharmaceutical Products: Mundipharma generates revenue through the development, manufacture, and sale of prescription pharmaceutical products across therapeutic areas including pain management, respiratory, oncology, and infectious diseases. The company operates through a global network of independent associated companies.
  2. DefenCath: CorMedix reported record 2025 net sales of approximately $260 million driven by DefenCath's TDAPA reimbursement. CorMedix is Mundipharma's US licensee for REZZAYO.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Mundipharma product offering

Product offering

Core offering

Mundipharma develops, manufactures, and commercializes prescription pharmaceutical products across four core therapeutic areas: pain management (opioid and non-opioid analgesics such as oxycodone and morphine formulations), respiratory conditions (asthma/COPD inhalers), oncology (treatments and supportive care), and infectious diseases (antifungal prophylaxis including REZZAYO). The company operates through a network of independent associated companies distributing products in 40+ countries.

Product overview

Mundipharma is a global pharmaceutical company with a diversified portfolio of prescription medicines and consumer health products. The company operates as a network of independent associated companies and focuses on specialty healthcare solutions. Their therapeutic areas include pain management (opioid analgesics such as OxyContin, OxyNorm, MST Continus, Zytram, Targin), respiratory treatments (Flutiform for inhalation), oncology (Zevalin, Pelmeg), and infectious diseases (REZZAYO antifungal). The portfolio comprises both proprietary developed products and licensed brands, with products available across multiple international markets through their global office network spanning over 40 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • REZZAYO: Antifungal medication (rezafungin) for invasive fungal infections
  • Mundipharma Pride

Products and services

  • REZZAYO (rezafungin) Antifungal medication for the prophylaxis and treatment of invasive fungal diseases, including for patients undergoing allogeneic hematopoietic stem cell transplantation. Co-developed with CorMedix.
  • Flutiform (fluticasone propionate/formoterol fumarate) Pressurized metered-dose inhaler for the management of asthma and COPD, available in 50/5µg, 125/5µg, and 250/10µg dosage strengths. Licensed from Jagotec AG.
  • MST Continus (morphine sulfate) Prolonged-release morphine sulfate tablets for pain management, available in 5mg, 10mg, 15mg, 30mg, 60mg, 100mg, and 200mg dosages.
  • OxyContin (oxycodone hydrochloride) Prolonged-release oxycodone tablets for chronic pain management, available in 5mg, 10mg, 20mg, 40mg, and 80mg dosages.
  • OxyNorm (oxycodone hydrochloride) Injectable oxycodone solution and infusion for acute pain management, available as 10mg/ml solution in 1ml and 2ml ampoules.
  • Zytram (tramadol hydrochloride) Prolonged-release tramadol tablets for pain management, available in 150mg, 200mg, 300mg, and 400mg dosages.
  • Zytram BID (tramadol hydrochloride) Prolonged-release tramadol tablets for pain management, available in 75mg twice-daily dosage.
  • TARGIN (oxycodone/naloxone) Combination prolonged-release oxycodone/naloxone tablets used in pain management.
  • BUTRANS (buprenorphine transdermal) Registered transdermal pain management product of the Mundipharma network.
  • ZEVALIN Registered oncology product in the Mundipharma network used in cancer treatment.
  • PELMEG (pegfilgrastim) Registered oncology supportive-care biosimilar in the Mundipharma network.

Quantifiable outcome

  • 60.7% fungal-free survival at Day 90 for REZZAYO versus 59.0% for standard regimen in Phase III ReSPECT trial
  • +1 more outcomes

Companies that use Mundipharma

Customer profile

Segments5 records

Ideal customer profiles1 record

Mundipharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Mundipharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CorMedix TherapeuticscoreStrategic or Co-development Partner · 27 April 2026Mundipharma and CorMedix partnered on the development and commercialization of REZZAYO (rezafungin) for prophylaxis of invasive fungal diseases. The Phase III ReSPECT trial met its primary endpoint demonstrating non-inferiority with 60.7% fungal-free survival at Day 90. The companies plan to submit for FDA approval in 2H26 and EMA approval in Q3 2026. The US market opportunity is estimated to exceed $2 billion.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Mundipharma competitors and assessment

Company assessment

Direct peers

  • Mallinckrodt: Specialty pharmaceutical company with branded specialty franchises including pain management. Operates across multiple therapeutic areas with a similar specialty-pharma profile to Mundipharma, including legacy opioid exposure.
  • Purdue Pharma: Pharmaceutical company historically anchored by OxyContin and other opioid analgesics, sharing therapeutic focus and brand portfolio overlap with Mundipharma's pain franchise. Closely comparable on opioid product positioning.
  • Grünenthal: Privately-held German specialty pharmaceutical company with a strong pain management franchise (including branded opioid and non-opioid analgesics) and global commercial operations. Highly comparable to Mundipharma in therapeutic focus and privately-held, specialty-pain-led business model.
  • Endo International: Specialty pharmaceutical company with significant pain management portfolio (including opioid analgesics) and branded specialty franchises. Comparable to Mundipharma across pain management focus and specialty pharma positioning, though Endo has faced opioid-related litigation.

Emerging players

  • Cidara Therapeutics: Clinical-stage biotechnology company developing antifungal therapies including rezafungin-related programs. Directly comparable to REZZAYO's therapeutic area and competitive positioning in the antifungal space.

Regional players

  • Hikma Pharmaceuticals: Specialty pharmaceutical company with strong presence in Middle East, North Africa, and other regional markets, plus specialty injectable and branded portfolio. Comparable to Mundipharma on specialty pharma positioning with regional market overlap.

Broad incumbents

  • Stada Arzneimittel: European-headquartered specialty pharmaceutical company with consumer health and specialty care portfolio across multiple therapeutic areas. Comparable as a European specialty pharma peer with similar multi-country distribution model.
  • Viatris: Global pharmaceutical company with broad specialty and generics portfolio across multiple therapeutic areas. Comparable to Mundipharma's diversified specialty/generic-style positioning across pain, respiratory, and other areas.
  • Astellas Pharma: Global pharmaceutical company with established antifungal franchise and specialty care portfolio. Comparable as a broader incumbent in antifungal/anti-infective therapeutics where REZZAYO competes, and a meaningful peer in specialty pharma.
  • GSK (GlaxoSmithKline): Global pharmaceutical major with established respiratory franchise (including inhaler products competing with Flutiform) and broad specialty portfolio. Comparable as a broad incumbent in respiratory therapeutics where Mundipharma operates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Mundipharma social profiles

Digital presence

Mundipharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mundipharma leadership team

Management profile

Number of profiles

Profiles9 records

Mundipharma subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Mundipharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mundipharma M&A and investment

M&A and investment

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mundipharma

What does Mundipharma do?

Mundipharma develops, manufactures, and commercializes prescription pharmaceutical products across four core therapeutic areas: pain management (opioid and non-opioid analgesics such as oxycodone and morphine formulations), respiratory conditions (asthma/COPD inhalers), oncology (treatments and supportive care), and infectious diseases (antifungal prophylaxis including REZZAYO). The company operates through a network of independent associated companies distributing products in 40+ countries.

Is Mundipharma a public or private company?

Mundipharma is a private company. It is classified as family owned and is currently operating.

When was Mundipharma founded?

Mundipharma was founded in 1992. It employs 1,001 to 5,000 people.

Where is Mundipharma based?

Mundipharma is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Mundipharma make money?

Two revenue lines are on record. Prescription Pharmaceutical Products are the primary driver. The others are defenCath.

Who are Mundipharma's main competitors?

Direct peers on record are Mallinckrodt, Purdue Pharma, Grünenthal and Endo International. Cidara Therapeutics is listed as an emerging player. Hikma Pharmaceuticals is listed as a regional player. Broad incumbents are Stada Arzneimittel, Viatris, Astellas Pharma and GSK (GlaxoSmithKline).

Does Mundipharma have an API?

No public API is recorded for Mundipharma.

What industry is Mundipharma in?

Mundipharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LelezardMundipharma annonce de nouveaux résultats de l'étude de phase III ReSPECT, présentés dans le cadre d'une présentation orale de dernière minute à l'IDWeek 2026Mundipharma presented new phase III ReSPECT results at IDWeek 2026, showing rezafungine was non-inferior to standard antimicrobial prophylaxis for invasive fungal infections after allogeneic stem cell transplant. The 90-day fungal-free survival was 60.7% with rezafungine versus 59.0% with standard, a 1.6% difference. Data were submitted to the FDA and EMA for regulatory review.Business & FinancialMundipharma Announces Further Phase III Respect Results Presented As A Late-Breaking Oral Presentation At Idweek 2026 -...Mundipharma presented Phase III ReSPECT results at IDWeek 2026, showing rezafungin non-inferior to standard antimicrobial regimen for fungal-free survival at Day 90 in allo-HSCT patients. FFS was 60.7% with rezafungin versus 59.0% with standard, and data were submitted to FDA and EMA for review.Financial PostMundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 2026Mundipharma presented additional Phase III ReSPECT trial results for rezafungin prophylaxis in allogeneic HSCT patients at IDWeek 2026. The trial met its primary endpoint, showing non-inferior fungal-free survival at Day 90 (60.7% vs 59.0%). Data have been submitted to the FDA and EMA for regulatory review.FinancialContent Business PageMundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 2026Mundipharma announced additional Phase III ReSPECT trial results for rezafungin prophylaxis in allogeneic HSCT patients, presented at IDWeek 2026. The study met its primary endpoint, showing non-inferior fungal-free survival at Day 90 (60.7% vs 59.0%). Data were submitted to FDA and EMA for review, with a US PDUFA target in Q1 2027.BenzingaCorMedix Stock Jumps on Strong DefenCath Sales - Cormedix (NASDAQ:CRMD)CorMedix Inc. reported strong second-quarter results, with adjusted earnings of 29 cents per share and revenue doubling to $101.9 million, driven largely by DefenCath sales. The company also announced a collaboration with Mundipharma for the FDA submission of an expanded indication for its drug REZZAYO in the third quarter. Additionally, CorMedix reaffirmed its fiscal 2026 sales guidance while increasing its adjusted EBITDA forecast.EIN Presswire[2026] Povidone Iodine Market Growing at a CAGR of 4.7% to 2031, Says AMRAllied Market Research projects the global povidone iodine market to reach $242.2 million by 2031, growing at a 4.7% CAGR from 2022 to 2031. The market was valued at $152.6 million in 2021. Key players include Avrio Health, 3M, and BASF.FuturismA Member of Sackler Family Says She Got Addicted to OpioidsJoss Sackler, wife of former Purdue Pharma board member David Sackler, pleaded guilty to a single felony count of obstructing a federal grand jury investigation after being caught receiving an illegal shipment of prescription drugs in 2024, facing up to 20 years in prison. The guilty plea comes as the Sackler family finalizes a $6.5 billion settlement over their role in Purdue Pharma's production of addictive opioids, with the company itself shuttered last week after reaching a $7.4 billion settlement. The case adds to the broader opioid epidemic that has claimed more than 800,000 lives in the US alone, with some Sacklers reportedly still holding positions at the international drug consortium Mundipharma.The Pharma LetterRezzayo Phase III data puts transplant prevention use in viewMundipharma and CorMedix reported positive Phase III data for Rezzayo, showing non-inferiority to standard antimicrobial care in preventing infections after allogeneic stem cell transplants. Fungal-free survival at Day 90 was 60.7% with Rezzayo versus 59.0% for standard care.FiercePharmaMundipharma, CorMedix eye antifungal expansion after Rezzayo trial winMundipharma and CorMedix announced that their antifungal drug Rezzayo met its primary endpoint in the phase 3 ReSPECT study, demonstrating non-inferiority to a standard antimicrobial regimen in preventing invasive fungal diseases in allogeneic stem cell transplant patients, with 60.7% fungal-free survival at Day 90 versus 59%. The trial included patients at 50 centers across seven countries. The companies plan to meet with the FDA in coming months and file for U.S. approval in the second half of this year, with a European Medicines Agency filing expected by Q3.Business Wire BlogMundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell tranMundipharma announced positive topline results from the global Phase III ReSPECT trial evaluating REZZAYO (rezafungin) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic haematopoietic stem cell transplantation. The trial met its primary endpoint, demonstrating non-inferiority of once-weekly rezafungin versus standard antimicrobial regimen in fungal-free survival at Day 90 (60.7% vs 59.0%). Mundipharma and its US licensee CorMedix intend to submit a supplemental New Drug Application to the FDA in 2H26 and expect an EMA submission in Q3 2026.